Rituximab

• 

  Subject Areas on Research

  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. 
  • A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. 
  • A Case of Probable Multifocal Motor Neuropathy With Clinical Stability for Ten Years After a Single Treatment of Rituximab. 
  • A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. 
  • A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. 
  • A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. 
  • A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. 
  • A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. 
  • A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. 
  • A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. 
  • A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). 
  • Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. 
  • Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. 
  • Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network. 
  • Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. 
  • Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. 
  • An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. 
  • Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. 
  • Anti-Myelin Oligodendrocyte Glycoprotein Optic Neuritis or Neuroretinitis? 
  • Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work? 
  • Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. 
  • Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. 
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. 
  • B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. 
  • B cells in chronic graft-versus-host disease. 
  • B cells in chronic graft-versus-host disease. 
  • B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. 
  • B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. 
  • B-lymphocyte contributions to human autoimmune disease. 
  • Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort. 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Biologic predictors of clinical improvement in rituximab-treated refractory myositis. 
  • Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. 
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. 
  • CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. 
  • CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. 
  • CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 
  • CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL). 
  • Cardiac Allograft Vasculopathy: A Formidable Foe. 
  • Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. 
  • Cellular targeting in autoimmunity. 
  • Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. 
  • Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. 
  • Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. 
  • Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. 
  • Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. 
  • Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. 
  • Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab. 
  • Cutaneous Lupus Erythematosus: Progress and Challenges. 
  • Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. 
  • Designs for randomized phase II clinical trials with two treatment arms. 
  • Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. 
  • Diagnosis and management of pemphigus: Recommendations of an international panel of experts. 
  • Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. 
  • Differential effects of donor-specific alloantibody. 
  • Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. 
  • Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. 
  • EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. 
  • Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. 
  • Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. 
  • Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 
  • Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. 
  • Efficacy of remission-induction regimens for ANCA-associated vasculitis. 
  • Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. 
  • Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. 
  • Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. 
  • Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response. 
  • Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. 
  • Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. 
  • Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. 
  • Good and bad memories following rituximab therapy. 
  • HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). 
  • Hairy cell leukemia: an elusive but treatable disease. 
  • Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy. 
  • How I treat thrombocytopenia in pregnancy. 
  • Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. 
  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. 
  • Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. 
  • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. 
  • Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. 
  • IgG4-related disease and intracranial hypertenstion: Case report of a novel mechanistic association. 
  • Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome. 
  • Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 
  • Immunosuppressive therapies in myasthenia gravis. 
  • Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. 
  • Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. 
  • In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months. 
  • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. 
  • Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. 
  • International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. 
  • Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. 
  • Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. 
  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. 
  • Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. 
  • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. 
  • Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. 
  • Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. 
  • MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. 
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. 
  • Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma. 
  • MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. 
  • MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. 
  • Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. 
  • Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. 
  • Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 
  • Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). 
  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: Presentation and outcomes of adults at a single center. 
  • Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. 
  • NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. 
  • Non-Hodgkin's lymphomas, version 2.2014. 
  • Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. 
  • Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. 
  • Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. 
  • Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. 
  • Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. 
  • Pediatric rheumatologists' perspectives on diagnosis, treatment, and outcomes of Sjögren disease in children and adolescents. 
  • Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome. 
  • Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. 
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. 
  • Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. 
  • Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. 
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. 
  • Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. 
  • Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. 
  • Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. 
  • Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. 
  • Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. 
  • Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. 
  • Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. 
  • Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. 
  • Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. 
  • Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. 
  • Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. 
  • Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. 
  • Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. 
  • Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. 
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). 
  • Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Recent advances in de novo CD5+ diffuse large B cell lymphoma. 
  • Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. 
  • Recurrent schilder's disease. 
  • Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. 
  • Regulatory B10 Cells Increase after Rituximab Therapy but Not after Conventional Immunosuppression in Patients with Pemphigus. 
  • Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? 
  • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. 
  • Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. 
  • Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients. 
  • Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. 
  • Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP). 
  • Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. 
  • Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Rituximab in lymphocyte predominance Hodgkin's disease: a case series. 
  • Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. 
  • Rituximab monotherapy to treat intravascular large B-cell lymphoma manifesting as pruritic calf patch in an elderly female. 
  • Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. 
  • Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • Rituximab-associated progressive multifocal leukoencephalopathy after lung transplantation. 
  • Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. 
  • Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. 
  • Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. 
  • Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. 
  • Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era. 
  • Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination. 
  • Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. 
  • Stromal gene signatures in large-B-cell lymphomas. 
  • Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). 
  • Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. 
  • Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. 
  • Targeted therapies for cancer 2004. 
  • The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 
  • The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. 
  • The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. 
  • The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series. 
  • The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease. 
  • The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. 
  • The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. 
  • Therapeutic vaccines for aggressive B-cell lymphoma. 
  • Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. 
  • Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. 
  • Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. 
  • Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. 
  • Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. 
  • Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. 
  • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. 
  • Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. 
  • Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. 
  • Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. 
  • Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. 
  • [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. 
  • p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.